The study was aimed to provide a prospective, long-term, randomized-controlled clinical comparison between the bipolar plasma vaporization of the prostate (BPVP), bipolar transurethral resection in saline (TURis) and monopolar transurethral resection of the prostate (TURP) in medium size benign prostatic hyperplasia (BPH) cases.
INTRODUCTION AND OBJECTIVES:
The study was aimed to provide a prospective, long-term, randomized-controlled clinical comparison between the bipolar plasma vaporization of the prostate (BPVP), bipolar transurethral resection in saline (TURis) and monopolar transurethral resection of the prostate (TURP) in medium size benign prostatic hyperplasia (BPH) cases.
METHODS: A total of 510 BPH patients with maximum flow rate (Qmax) <10 mL/s, International Prostate Symptom Score (IPSS) >19 and prostate volume between 30 and 80 mL were prospectively enrolled and equally randomized in the 3 study arms. All cases were evaluated preoperatively and every 6 months for a 8 years' follow-up period by IPSS, quality of life score (QoL), Qmax, abdominal ultrasound measuring the prostate volume and post-voiding residual urinary volume (PVR) and prostate specific antigen (PSA).
RESULTS: Similar preoperative parameters were outlined in the 3 series. The capsular perforation (1.2% vs. 7.1% and 9.4%) and mean hemoglobin level drop (0.5 vs. 1.2 and 1.6 g/dL) were significantly decreased for BPVP by comparison with TURis and TURP. The postoperative hematuria (2.9% and 4.7% vs. 15.3%) and urinary retention (0.6% and 1.2% vs. 4.1%) rates were significantly higher in the TURP group. The mean catheterization period (23.5 vs. 46.3 and 72.8 hours) and hospital stay (1.9 vs. 3.1 and 4.2 days) were significantly reduced for BPVP, followed by TURis. The rates of irritative symptoms (12.4% vs. 11.2% and 10.6%) and urethral strictures (4.7% vs. 6.5% and 5.3%) were similar in the 3 series. During the 6, 12 and 18 months' follow-up, BPVP patients benefitted from significantly superior IPSS and Qmax results, while these differences lost statistical significance at the 2 to 8 years' evaluations. Similar QoL scores and PVR values were described during all the periodical check-ups. Equivalent PSA and prostate volume reductions (compared to the initial assessment) were determined in the 3 series.
CONCLUSIONS: The plasma vaporization constitutes a viable alternative to mono-and bipolar resection in medium size BPH cases, providing the advantages of superior surgical safety, reduced perioperative hemorrhagic risks and faster postoperative recovery. Despite the BPVP medium term improved IPSS and Qmax, the 8 years' followup emphasized equivalent symptomatic and functional profiles. Similar prostate ablation capacities were described.
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MP45-20 IS AQUABLATION OF THE PROSTATE EFFECTIVE IN PATIENTS WITH RECURRENT RETENTION?
Thorsten Bach*, Hamburg, Germany; Iannis Giannakis, Frauenfeld, Switzerland; Magdalena Karimi, Hamburg, Germany; Enrique Rijo, Barcelona, Spain INTRODUCTION AND OBJECTIVES: Aquablation, an autonomous tissue removal system for the treatment of BPO has proven efficacy in men with obstructive voiding, but without retention. The aim of this prospective data collection was to evaluate the outcome of Aquablation in men with recurrent urinary retention and indwelling catheter and men undergoing Aquablation due to BPO without retention.
METHODS: This single-centre observation included all patients with previous retention (Rþ) undergoing Aquablation therapy and evaluated perioperative course, morbidity and symptom relief after three months. Outcome was compared to a consecutive cohort of patients without retention (R-) treated in the same time interval.
RESULTS: 48 consecutive patients with and without retention have been. Age (69.6 (Rþ) vs. 69.5 (R-) yrs) was comparable between both groups. Prostate volume was significantly higher in the retention group (85.9 (Rþ) vs. 65.5 cc (R-). However, treatment time was comparable with a mean TRUS to Foley time of 21.7 (Rþ) vs. 21.4 min (R-) and a mean Aquablation time of 5.3 (Rþ) vs. 3.1 min (R-). Outcome data is displayed in Table 1 . Postoperative catheter time was 2.4 (Rþ) vs. 2.3 d (R-). Cautery, due to delayed bleeding was needed in 3 (Rþ) vs. 2 (R-) patients and a higher rate of discharge with suprapubic tube occurred in the patients with preoperative retention (16.7 (Rþ) vs. 4.2% (R-)).
CONCLUSIONS: Aquablation is safe and effective also in patients with recurrent retention and indwelling catheter. The ASCO Quality Oncology Practice Initiative is an oncologist-led practice-based quality assessment program to promote excellence in cancer care. A total of 994 practices submit data on over 32,000 patients. We utilized their dataset to identify the proportion and predictors of discussing fertility risks and fertility preservation prior to initiating cancer therapy among patients of reproductive age.
METHODS: Reproductive age was defined as 18-40 and 18-50 for females and males, respectively. We assessed whether fertility risks and fertility preservation options were discussed prior to chemotherapy with patients of reproductive age. We also assessed whether a referral to a specialist was made. Multivariable linear regression was performed to identify predictors of fertility preservation counselling controlling for practice type (academic vs. private), geographic location (region and state) and state legislature mandating insurance coverage for fertility preservation.
RESULTS: A total of 136,746 charts were reviewed with a total of 27,052 patients identified as being of reproductive age. Overall, 41.8% of patient of reproductive age had a discussion regarding the risk of infertility associated with chemotherapy while 27.7% of patients had fertility preservation options discussed or were referred to a specialist. On
